Anne Luquette

Cooley advised io Products, an engineering and product manufacturing company co-founded by Jony Ive to develop, engineer and manufacture a new family of products for the artificial general intelligence era, on its approximately $6.5 billion acquisition by OpenAI. As part of the deal, Ive and his creative collective, LoveFrom, will assume deep design and creative responsibilities across OpenAI. 

Cooley advised BioMarin Pharmaceutical (Nasdaq: BMRN), a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient, on its definitive agreement to acquire Inozyme Pharma for $4 per share in an all-cash transaction valued at approximately $270 million.

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Cooley advised Confluent, a data-streaming platform pioneering a fundamentally new category of data infrastructure that sets data in motion, on its acquisition of WarpStream, an Apache Kafka-compatible data-streaming platform.

Cooley advised WSO2, a leading provider of application development and identity and access management software to enterprise companies globally, on its agreement to be acquired by EQT’s BPEA Fund VIII (EQT Private Capital Asia).